Safety and efficacy of high dose atg bolus administration on rewascularization in kidney graft patients - long term results

Annals of Transplantation

Volumn 13, Issue 1, 2008, Pages 32-39

  Samsel, Radoslaw ^a   Pliszczynski, Jacek ^a   Chmura, Andrzej ^a   Korczak, Grazyna ^b   Wlodarczyk, Zbigniew ^c   Cieciura, Tomasz ^a   Lagiewska, Beata ^a   Glyda, Maciej ^d   Wyzgal, Janusz ^a   Paczek, Leszek ^a   Durlik, Magdalena ^a   Rowiński, Wojciech ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b UNIVERSITY OF WARSAW   (Poland)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^d Province Hospital Pozna   (Poland)

Author keywords

ATG; Immunosuppressive regimen; Renal transplantation

Indexed keywords

AZATHIOPRINE; CELL CEPT; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIPERACILLIN; PREDNISONE; TAZOBACTAM; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BACTERIAL PNEUMONIA; BODY TEMPERATURE; BREAST CANCER; BREATHING RATE; CADAVER; CANDIDIASIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DYSPNEA; ENTERITIS; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; FUNGEMIA; GRAFT RECIPIENT; GRAFT SURVIVAL; HERPES SIMPLEX; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE INFECTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SUPPURATION; SURVIVAL TIME; SWELLING; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; THRUSH; URINARY TRACT INFECTION; URINE VOLUME; VIRAL SKIN DISEASE; WEIGHT GAIN; CLASSIFICATION; DRUG COMBINATION; GRAFT REJECTION; LENGTH OF STAY; MIDDLE AGED; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; SAFETY; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; ANTILYMPHOCYTE SERUM; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SAFETY; TREATMENT OUTCOME;

EID: 48549092259     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Woodruff MFA, Anderson NA: Effect of lymphocyte depletion by thoracic duct fi stula and administration of anti-lymphocyte serum on the survival of skin homografts in rats. Nature, 1963; 200: 702
2. Starzl TE, Marchioro TL, Porter KA et al: The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplanatation. Surgery Gynecology and Obstetric, 1967; 123: 301-18
3. Shield CF, Edwards EB, Davies DB, Daily OP: Antilymphocyte induction therapy in cadaver renal transplantation. A Retrospective Multicenter United Network For Organ Sharing Study. Transplantation, 1997; 63: 1257-63
4. de Ligny BH, Lebranchu Y: The use of Thymoglobuline induction in renal transplantation a pharmacovigilance study. Transplantation Proceedings, 2000; 32: 351-52
5. Bock HA, Gallati H, Zurcher RM et al: Randomized prospective trial of prophylactic immunosuppression with ATG-Fresenius S vesus OKT 3 after renal transplantation. Transplantation, 1995; 59: 830-40
6. Kaden J, May G, Schonemann C et al: Effect of ATG prophylaxis in sensitized and non - sensitized kidney graft recipients. Transplant International, 1992; 5(Suppl.1): 75-78
7. Kaden J, May G, Muller P et al: Intraoperative High- Dose Anti-T-Lymphocyte Globulin Bolus in Adition to Triple-Drug Therapy Improves Kidney Graft Survival. Transplantation Proceedings, 1995; 27: 1060-61
8. Kaden J, May G, Stobelt V et al: Intraoperative T-Cell Depletion Prior to Completion of Anastomoses by High-Dose Single ATG Bolus as a New Approach to improve Long-Term results After Kidney Transplantation. Transplantation Proceedings, 1997; 29: 344-47
9. Rubin RH: Infectious complications of renal transplantation. Kidney International, 1993; 44: 221-36
10. Lange H, Muller TF, Ebel H et al: Immediate and long term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Transplant International, 1999; 12: 2-9
11. Norrby J, Olausson M: A randomized clinical trial using ATG Fresenius or ATG Merieux as induction therapy in kidney transplantation. Transplantation Proceedings, 1997; 29(7): 3135-36
12. Siennicka J, Durlik M, Litwińska B et al: Usefulness of Hybridization and PCR Methods in Monitoring of CMV Infection in Renal Transplant Recipients. Ann Transplant, 2000; 1: 21-24
13. Durlik M, Siennicka J, Litwińska B et al: Comparison of antigenemia (pp65) assay and polymerase chain reaction in diagnosis of cytomegalovirus infection in renal transplant recipients treated with ATG. Tarnsplantation Proceedings, 2000; 6: 1350-52
14. Durlik M, Siennicka J, Litwińska B et al: Clinical manifestations and diagnosis of cytomegalovirus infection in allograft recipients. Tarnsplantation Proceedings, 2001; (1-2): 1237-39
15. Hibberd AD, Trevillian PR, Wlodarczyk JH et al: Cancer Risk Associated With ATG/OKT3 In Renal Transplantation. Transplantation Proceedings, 1999; 31: 1271-72
16. Opeltz G, Henderson R: Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet, 1993; 342: 1514-16
17. Cockfield SM, Preiksaitis J, Harvey E et al: Is sequential use of ALG and OKT 3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder. Transplantation Proceedings, 1991; 23: 1106-7
18. Kaden J, Strobelt V, May G: Short and long-term results after pretransplant high-dose single ATGFresenius bolus in cadaveric kidney transplantation. Transplantation Proceedings, 1998; 30: 4011-14
19. Kaden J, May G, Schonemann C et al: Effect of ATG prophylaxis in sensitized and non - sensitized kidney graft recipients. Transplant International, 1992; 5(Suppl.1): 75-78
20. Szczech LA, Berlin JA, Feldman HI for Anti- Lymphocyte Antibody Induction Therapy Study Group: The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Ann Intern Med, 1998; 128(10): 817-26
21. Gaston RS, Shroyer TW, Hudons SL et al: Renal retransplantation: the role of race, quadriple immunosuppression and fl ow cytometry cross-match. Transplantation, 1994; 57: 7-54
22. Cardella CJ, Cattran D, Fenton SA et al: Induction therapy with rabbit antithymocyte sera reduces rejection episodes in immunologically low-risk living donor renal transplant recipients. Transplantation Proceedings, 1997; 29(7A): 29S-31S
23. Opelz G: Efficiacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation, 1995; 60: 1220-24
24. Mozes MF, Venkat KK, Kupin W et al: Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation. Transplantation Proceedings, 1993; 25: 575-76
25. Shield CF, Edwards EB, Davies DB, Daily OP: Antilymphocyte induction therapy in cadaver renal transplantation. A Retrospective Multicenter United Network For Organ Sharing Study. Transplantation, 1997; 63: 1257-63
26. Cecka JM, Cho YW, Terasaki PI: Analysis of theUNOS scientifi c renal transplant registry at three years-early events affecting transplant success. Transplantation, 1992; 53: 59-64
27. Szczech LA, Feldman HI: Effect of anti-lymphocyte antibody induction therapy on renal allograft survival. Transplantation Proceedings, 1999; 31(Suppl.B): 9S-11S
28. Thibaudin D, Alamartine E, de Filipis J-P et al: Advantage of antithymocyte globulin induction in sensitised kidney recipients: a randomised prospective study comparing induction with and without antithymocyte globulin. Nephrology Dialysis Transplantation, 1998; 13: 711-15
29. Lange H, Muller TF, Ebel H et al: Immediate and long term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Transplant International, 1999; 12: 2-9